RYTHM (NASDAQ:RYM – Get Free Report) is one of 894 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare RYTHM to similar companies based on the strength of its earnings, analyst recommendations, valuation, risk, institutional ownership, profitability and dividends.
Profitability
This table compares RYTHM and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| RYTHM | 9.84% | 21.25% | 5.51% |
| RYTHM Competitors | -2,391.71% | -204.89% | -14.89% |
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for RYTHM and its rivals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| RYTHM | 1 | 0 | 0 | 0 | 1.00 |
| RYTHM Competitors | 7870 | 13817 | 25857 | 1043 | 2.41 |
Institutional & Insider Ownership
6.0% of RYTHM shares are held by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 3.5% of RYTHM shares are held by insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Valuation & Earnings
This table compares RYTHM and its rivals top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| RYTHM | $70.82 million | -$33.26 million | -1.82 |
| RYTHM Competitors | $18.55 billion | $3.23 billion | 560.54 |
RYTHM’s rivals have higher revenue and earnings than RYTHM. RYTHM is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Volatility and Risk
RYTHM has a beta of 9.94, suggesting that its stock price is 894% more volatile than the S&P 500. Comparatively, RYTHM’s rivals have a beta of -0.05, suggesting that their average stock price is 105% less volatile than the S&P 500.
Summary
RYTHM rivals beat RYTHM on 9 of the 13 factors compared.
About RYTHM
I couldn’t verify a Nasdaq-listed company named RYTHM with the ticker RYM. If you mean Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM), it is a biopharmaceutical company developing treatments for rare genetic diseases and other conditions linked to the brain’s melanocortin-4 receptor pathway, which helps regulate hunger and body weight. Its marketed medicine, Imcivree (setmelanotide), is approved in the United States for certain forms of rare genetic obesity and acquired hypothalamic obesity. The company is based in Boston and focuses on developing and providing therapies for patients in the United States and other markets.
Receive News & Ratings for RYTHM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RYTHM and related companies with MarketBeat.com's FREE daily email newsletter.
